

Insight Pharma Reports Announces Prenatal Diagnostics Testing Report

Prenatal Diagnostics: Invasive testing, noninvasive testing, and rising maternal screening methods for preeclampsia and preterm labor

NEEDHAM, MASSACHUSETTS, UNITED STATES, February 5, 2014 /EINPresswire.com/ -- NEEDHAM, MASS. – <u>Insight Pharma Reports</u> announces Prenatal Diagnostics: Invasive testing, noninvasive testing, and rising maternal screening methods for preeclampsia and preterm labor report. The newly released Insight Pharma Report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare.

In addition to covering several aspects of prenatal diagnostics, this report also includes specifications of particular instruments, exclusive interviews with CEOs, CSOs, and Vice Presidents of the participating companies, which Ariosa Diagnostics, Metabolomic Diagnostics Natera, NX PharmaGen, Sequenom, Silicon Biosystems Verinata Health. Specific areas of focus include company goals, customer feedback, challenges encountered, competitive advantage, platform pricing, and future endeavors. A survey capturing the demographics of the prenatal industry is presented at the end of the report, specifically highlighting organizational background, areas of research, challenges encountered, and applications in development.

For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com or contact Kerri Simpson at ksimpson@healthtech.com or 781-972-1347.

About Insight Pharma Reports

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.lnsightPharmaReports.com

Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit

http://www.insightpharmareports.com/affiliatedreports/

Kerri Simpson Cambridge Healthtech Institute 7819721347 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/189009069

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.